The companies announced that the minimum acceptance condition of Johnson & Johnson’s offer to acquire Crucell was satisfied.
When the offer expired on Feb. 16, the shares tendered in the deal represent 95 percent of the issued and outstanding share capital of Crucell on a fully diluted basis.
Johnson & Johnson noted in a prepared statement that "even though 95.24% of the issued and outstanding share capital of Crucell (on a fully diluted basis) has been tendered, the minimum acceptance condition would have nonetheless been satisfied because Johnson & Johnson has now obtained a favorable ruling from the Internal Revenue Service of the United States and, as of the expiration of the initial offering period, received proxies (or will have obtained the voting power) in respect of approximately 93.32% of Crucell shares."
Johnson & Johnson plans to announce whether or not its offer is declared unconditional no later than Feb. 22.
The companies on Feb. 8 announced that Crucell shareholders voted to adopt the governance resolutions of the company’s proposed acquisition by Johnson & Johnson.
Here’s a roundup of companies announcing mergers, acquisitions and divestitures.
- 21st Century Oncology acquires hyperthermia system from BSD
BSD Medical Corp. (NSDQ:BSDM) announced that 21st Century Oncology has purchased the BSD-500 Hyperthermia System. 21st Century Oncology is a leading provider of radiation therapy centers and operates 98 freestanding and hospital-based centers in the U.S. 21st Century Oncology centers provide a full spectrum of advanced treatments to cancer patients. Additionally, 21st Century Oncology’s doctors come from some of the most prestigious and recognized medical training centers and universities in the world and their senior radiation oncologists are nationally recognized for excellence and leadership in the field of radiation oncology. The purchase of the BSD-500 by 21st Century Oncology significantly increases the number of patients who will have access to hyperthermia treatment.
- MiMedx launches recently acquired Surgical Biologics technology
MiMedx Group Inc. (OTC:MDXG), an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced the launch of AmnioFix, the Company’s newest technology platform. MiMedx formally unveiled AmnioFix earlier today during the first day of the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting being held in San Diego, Calif.. MiMedx recently acquired its AmnioFix technology through the acquisition of Surgical Biologics, the leading processor of amniotic tissue and the developer of the patent-pending Purion process.
- 153-Year-Old Dohmen Company acquires PlanIT
Dohmen Company CEO Cynthia (Dohmen) LaConte announced that the Dohmen Investment Group acquired PlanIT Inc., a health care analytics company based in Germantown, Wis. LaConte said the purchase is the first of several planned with the intent of joining together a series of exceptional companies dedicated to creating efficiencies within health care. PlanIT co-founder Terry Adams will serve as division president.